Astria Therapeutics Advances HAE Treatment With Ypsomed’s YpsoMate For STAR-0215

Astria Therapeutics, a biopharma firm dedicated to advancing innovative treatments for allergic and immunological conditions, has revealed its selection of Ypsomed as its partner to develop an autoinjector for STAR-0215. Pending regulatory approval, Astria intends to introduce STAR-0215 with two administration options: the Ypsomed YpsoMate autoinjector and a pre-filled syringe. This dual offering will provide patients the flexibility to select the method that best fits their lifestyle. Astria considers the autoinjector an excellent option for STAR-0215, citing its user-friendly design, needle protection feature, and the unique formulation of STAR-0215, which ensures a swift and low-pain injection.

John Ruesch, Senior Vice President, Pharmaceutical Sciences and Technical Operations, added, “With STAR-0215's profile, our goal is to develop a therapy that allows patients to choose an approach that works best for their lives with the option of infrequent three- and six-month administration. Our partnership with Ypsomed, a leading developer and manufacturer of injection systems, supports this goal through the planned development of an autoinjector that enables our vision for STAR-0215 to be a therapy that can effectively protect against HAE attacks while also having a very low burden of treatment and administration.”